Breast Cancer

In a prospective pilot of 74 patients enriched for under-represented risk factors, 15-fraction breast/chest wall RT with SIB yielded 10-year LRFS of 93.1%, DMFS of 94.2%, and OS of 89.2%, with no grade 3 brachial plexopathy or significant lymphedema, supporting condensed SIB use in routine practice.

In 536,783 NCDB breast RT courses from 2020 to 2023, 5-fraction RT rose from 4.3% to 17.4% overall, with uptake significantly lower among uninsured patients (6.9%), Black patients (9.4% vs 12.2% White), and mid-size metro areas, revealing persistent access disparities.

Dosing has resumed in the INVINCIBLE-4 trial of INT230-6 plus standard therapy in early-stage triple-negative breast cancer.

In an NCDB cohort of 536,783 breast radiation courses from 2020 to 2023, 5-fraction RT utilization rose from 4.3% to 17.4%, with overall 10.7% adoption across the 4-year period.

This narrative review synthesizes evidence and sarcoma-based extrapolation to support multicatheter interstitial HDR brachytherapy as a feasible chest-wall irradiation strategy for selected high-risk malignant phyllodes tumors.

Geospatial analysis of 77 Miami-Dade zip codes found 49 containing no mammography facilities, with zero-facility areas concentrated in lower-income, majority-Hispanic/Latino and Black neighborhoods.

A Gaussian linear regression model of US county-level data found breast cancer mortality risk highest among African American individuals and those in rural, high-ADI counties.

The FDA has approved the gedatolisib combination for HR+/HER2– PIK3CA wild-type advanced breast cancer post-CDK4/6i, based on the phase 3 VIKTORIA-1 trial.

In a nationally representative cross-sectional analysis of 6774 women aged 40 to 49 years, overall mammography prevalence was 60.3% with no significant change from 2019 to 2023, while Hispanic women showed a 6.5-percentage-point decline and insurance status remained the strongest enabling factor for uptake.

In 77 biopsy-proven cystic breast lesions, radiologists achieved significantly higher diagnostic accuracy than the KOIOS DS™ AI tool for malignant cystic lesions (92% vs 76% BI-RADS/suspicious classification).

Mayo Clinic oncologists weigh first-line ADC options in metastatic TNBC, tackling biomarker timing, sequencing, and real-world toxicity management from fatigue to ocular events.

A 2-phase U-Net trained on abnormality-focused patches achieved a mean Dice coefficient of 0.58 and detected 77.8% of mammographic lesions on a 55-image test set, with 100% detection of large lesions but resolution-dependent failures for small abnormalities.

GBD 2023 data analysis found India’s age-standardized breast cancer incidence at 28.7 per 100,000 women, with national mortality tripling from 33,151 to 101,621 between 1991 and 2023 and DALYs quadrupling, with the steepest increases in Jharkhand and the highest incidence in Delhi.

This TIP study aims to validate Artera’s MMAI prognostic model—which integrates digital pathology images with clinical data from H&E slides—in patients with early-stage HR+/HER2− breast cancer, with enrollment at UAB anticipated to complete by April 2026.

Using the DISCERN tool, LLMs (ChatGPT and OpenEvidence) scored significantly higher than Google on breast pathology health information quality and reliability, with mean total DISCERN scores of 62.2 and 64.8 vs 35.9, supporting integration of AI tools for patient education.

A prospective subsidized breast biopsy and navigation program at a Kenyan referral hospital achieved same-day CNB in 100% of 104 patients with invasive breast carcinoma, revealing high rates of aggressive subtypes and median 8-month prediagnostic delays, with 16.35% mortality during follow-up.

Intraoperative surgeon-performed PECs block during mastectomy resulted in only 16.6% of patients requiring postoperative opioids, supporting this technique as a fast and effective method of regional analgesia.

In 278 patients with a positive family history of breast cancer followed for a median 96 months, local recurrence, regional recurrence, and CBC risk were comparable to general population rates by SIR analysis, with recurrence risk driven more by biological subtype than family history.

In 52 patients with multifocal upper inner quadrant breast cancer, a modified Würinger central pedicle mastopexy enabled large-volume oncoplastic resections with 80.8% patient satisfaction and significant BREAST-Q quality-of-life improvement, with no major infectious complications.

Advanced oncoplastic breast surgery using multiple pedicles for complex defect reconstruction demonstrated oncologic safety and acceptable complication rates in selected patients undergoing breast-conserving surgery.

Targeted axillary dissection with sentinel lymph node biopsy successfully retrieved all preoperatively identified positive nodes in node-positive breast cancer patients treated with neoadjuvant chemotherapy, with no axillary recurrences observed.

In 21 patients with metaplastic breast cancer receiving neoadjuvant chemotherapy, 48% achieved pCR—higher than prior estimates—with all pCR patients alive and disease-free at follow-up, suggesting modern regimens including pembrolizumab may improve outcomes in this chemoresistant subtype.

In 391 Venezuelan breast cancer patients receiving NACT, normal BMI was associated with higher pCR (31.6% vs 15.8% overweight and 14.7% obese) and significantly better OS at 120 months, supporting BMI as a relevant prognostic and predictive factor.

In this institutional retrospective review, 14.4% of clinically node-negative patients meeting SOUND trial criteria had nodal metastases on SLNB, underscoring the need for careful multidisciplinary decision-making before integrating axillary staging de-escalation into practice.

A retrospective review found progressive adoption of Choosing Wisely guidelines for sentinel lymph node biopsy omission in elderly patients with early-stage breast cancer, with younger age and earlier year of diagnosis as the strongest predictors of biopsy performance.